SCHEMBL144791

SCHEMBL144791

COc1ccc(C2=C(C(N)=O)C(=O)c3ccccc32)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 6/20 1.00
FGFR2 P21802 6/20 1.00
FGFR4 P22455 6/20 1.00
FGFR3 P22607 6/20 1.00
SRC P12931 4/20 1.00
CRHBP P24387 1/20 0.69
CRHR2 Q13324 1/20 0.69
HSP90AA1 P07900 7/20 0.60
MAPT P10636 4/20 0.60
MEN1 O00255 3/20 0.60
KMT2A Q03164 3/20 0.60
NPC1 O15118 2/20 0.60
TP53 P04637 2/20 0.60
RAB9A P51151 2/20 0.60
SMN1; SMN2 Q16637 2/20 0.60
TSHR P16473 1/20 0.60
KDM4E B2RXH2 1/20 0.60
ALDH1A1 P00352 1/20 0.60
LMNA P02545 1/20 0.60
MAPK1 P28482 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL144665 0.82 FGFR1 (1.00) FGFR1FGFR2FGFR4FGFR3SRC
SCHEMBL140758 0.80 FGFR1 (1.00) FGFR1FGFR2FGFR4FGFR3SRC
SCHEMBL14773924 0.75 ME2 (0.74) FGFR1FGFR2FGFR4FGFR3SRC
SCHEMBL16296996 0.75 MAPT (0.88) FGFR1FGFR2FGFR4FGFR3SRC
SCHEMBL2489785 0.75 MAPT (1.00) FGFR1FGFR2FGFR4FGFR3SRC
SCHEMBL6555686 0.74 FGFR1 (0.59) FGFR1FGFR2FGFR4FGFR3SRC
SCHEMBL4963646 0.73 BCAT2 (0.65) FGFR1FGFR2FGFR4FGFR3SRC
SCHEMBL5491718 0.73 FGFR1 (0.68) FGFR1FGFR2FGFR4FGFR3SRC
SCHEMBL4658483 0.72 PPARG (0.73) FGFR1FGFR2FGFR4FGFR3SRC
SCHEMBL143675 0.72 FGFR1 (1.00) FGFR1FGFR2FGFR4FGFR3SRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140221455-A1 DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR Verva Pharmaceuticals, Inc. (AU) 2014-08-07 US disclosed
US-20120059047-A1 DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR VERVA PHARMACEUTICALS PTY LTD (AU) 2012-03-08 US disclosed
US-20050282733-A1 Differentiation modulating agents and uses therefor VERVA PHARMACEUTICALS PTY LTD (AU) 2005-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120059047-A1 DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR FGF1, FABP4, FGF2 FGFR1 5/4885FGFR2 6/4885FGFR4 15/4885
US-20050282733-A1 Differentiation modulating agents and uses therefor FGF1, FABP4, FGF2 FGFR1 5/4885FGFR2 6/4885FGFR4 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.